Investor Presentaiton

HIF-PHI¹ class could become the new standard of care Daprodustat has the potential to deliver patient benefit across populations Non-dialysis dependent >1 million Patients treated in the US and Europe c.30% Patients with Hb <10g/dl treated with ESA 54% Treatment discontinuation in one year Dialysis dependent gsk >850 thousand Patients treated in the US and Europe c.12% Patients treated with home dialysis (expected to grow to 25% by 2025) c.12% ESA hypo responders 1. Hypoxia-inducible factor prolyl hydroxylase Inhibitors. Source: Epidemiology data derived from multiple sources, including: 1. https://www.thelancet.com/article/S0140-6736(20)30045-3/fulltext 2. Prevalence of Anemia in Chronic Kidney Disease in the United States (nih.gov) 3. Nephrol Dial Tranplant 2002, Suppl 11:44-6 4. https://www.nature.com/articles/s41598-020-79254-6, 5CKDopps. Sci Rep 11, 1784 (2021). https://doi.org/10.1038/s41598-020-79254-6, Spherix RealWorld Dynamix 20Q2 report. 22

View entire presentation